OPKO HEALTH, INC.

10% owner OPKO Health sells 139,824 shares of GeneDx (WGS) for $4.8M over 3 days as stock hits 52-week high.

OPKO Health, a 10% stakeholder in GeneDx, executed three separate sales totaling 139,824 shares for $4,756,875.36 between August 15–19, 2024 at prices ranging from $33.08 to $34.49 (blended average $34.02). This sale reduces OPKO's position from 2,786,796 shares to 2,646,972 shares, a -5.0% reduction. The timing coincides with the stock trading at its 52-week high of $35.53, which occurred after a strong 90-day rally of +71.2% and a 30-day gain of +11.6%. However, GeneDx faces material operational headwinds: the company reported negative net income of $-29,173,000.00 in the latest quarter and annual revenue declined -13.7% year-over-year. With the stock at peak valuation and the company unprofitable, OPKO's disposition of shares at market highs is noteworthy, though the 5% reduction preserves a substantial 2.65M-share holding, suggesting continued material ownership stakes rather than a full exit.

10% owner OPKO Health sells 84,774 shares (3% of stake) in WGS at $33.95–$34.76 for $2.9M as stock near 52-week high

OPKO Health, a 10% owner of GeneDx Holdings, executed 2 separate sales totaling 84,774 shares for $2,898,313.64 on 2024-08-12 and 2024-08-13, reducing holdings by 3.0% from 2,871,570 to 2,786,796 shares. The sales occurred at prices ($33.95 and $34.76) near the stock's 52-week high of $34.50, while the company is unprofitable (full-year net income: $-29,173,000.00), recording negative revenue growth of -13.7% year-over-year and recent quarterly net loss of $-29,173,000.00. The insider's cross-ticker track record shows an average 30-day return of +11.6% following prior sells, but the SAME-TICKER history at WGS comprises 5 recent sells (within the last ~2 weeks) with no yet-measurable outcomes, suggesting a pattern of sequential disposition activity at this holding. The timing of these sales—amid deteriorating fundamentals, near peak valuation, and following multiple recent reductions in the same position—merits close observation of whether this reflects evolving conviction regarding WGS prospects.

10% owner OPKO Health sells 112,994 shares at $29.35–$31.82 on unprofitable GeneDx (WGS); stock up 58.2% in 90 days.

OPKO Health, a 10% owner of GeneDx Holdings Corp., executed 2 separate sales totaling 112,994 shares for $3,563,807.18 on 2024-08-06 and 2024-08-08, reducing its stake by 3.8% to 2,871,570 shares. The timing of these sales follows a series of five consecutive sell transactions at this ticker between 2024-07-23 and 2024-07-31—a pattern that warrants attention, as the stock has since climbed 58.2% over 90 days and now trades at $32.83, near its 52-week high of $34.50. GeneDx remains unprofitable with a net loss of $-29,173,000.00 over its most recent full fiscal year and annual revenue declining 13.7% year-over-year, suggesting the insider disposed of shares during a period of stock appreciation despite deteriorating fundamentals. Across OPKO's cross-ticker open-market history, prior sales have averaged a positive 30-day return of +11.6%, but the same-ticker outcomes at WGS cannot yet be measured, making it unclear whether this pattern of sequential sales represents a portfolio adjustment or a tactical response to near-term valuation.

OPKO HEALTH (10% owner) sold 88,839 WGS shares at $33.50 on 2024-07-31; stock now $30.07, down -12.8% from high.

A 10% holder of GeneDx divested 88,839 shares (2.9% of pre-transaction holdings) on July 31, 2024 at $33.50, reducing the stake from 3,073,403 to 2,984,564 shares. The company faces material headwinds: annual revenue contracted -13.7%, the latest quarter saw $-29.2M net income against $70.5M quarterly revenue, and the stock has declined -12.8% from its 52-week high of $34.50, now trading at $30.07. This sale occurred within a burst of five consecutive daily exits by the same insider from July 22–29 (all outcomes not yet measurable), suggesting a deliberate unwinding pattern rather than an isolated transaction. The insider's cross-ticker track record shows 10 prior open-market sells with an average 30-day return of +13.4%, but same-ticker timing cannot yet be assessed given the recent dates of these sales.

10% Owner OPKO HEALTH sold 50,000 WGS shares at $33.86 on 2024-07-29; stock down -5.2% from 52-week high, company unprofitable with -13.7% annual revenue decline

OPKO HEALTH, a 10% shareholder, sold 50,000 shares (50.0K shares) of GeneDx Holdings Corp. at $33.86 on 2024-07-29, reducing its stake by -1.6% to 3,073,403 shares (3.07M shares) post-transaction. The sale occurred near GeneDx's 52-week high of $34.50, with the stock currently trading at -5.2% from peak and up 67.8% over 90 days. Notably, GeneDx is operating at a structural loss with latest-quarter net income of $-29,173,000.00 ($-29.2M) against quarterly revenue of $70,514,000.00 ($70.5M), and the company has contracted -13.7% in annual revenue. The insider's cross-ticker sales history shows an average 30-day post-sale return of +22.8%, suggesting a pattern of selling into strength, though GeneDx-specific measurable outcomes are not yet available for the five consecutive sales (July 22–31, 2024).

10% holder OPKO Health sells 135,000 WGS shares over 4 days for $4,560,363 as stock rallies +202.6% in 90 days

OPKO Health, a 10% shareholder of GeneDx Holdings Corp., executed 2 separate sales totaling 135,000 shares for $4,560,363.00 on July 24 and July 26, 2024, at prices of $33.72 and $33.85 respectively, reducing holdings by 4.1% from 3,258,403 to 3,123,403 shares. The timing of these sales is noteworthy: they occurred amid a 90-day surge of +202.6% and within 2.8% of the 52-week high of $34.50, suggesting the sales captured significant accumulated gains. However, the company fundamentals remain weak—annual revenue declined 13.7% year-over-year to $62,422,000.00, with a loss of $20,239,000.00 in the latest quarter and full-year net income negative—raising questions about whether the stock's recent rally reflects sustainable improvement or temporary momentum. The fact that OPKO initiated a sequence of sales at this ticker across multiple consecutive trading days (July 3, 5, 19, 22, 23, and now July 24–26) while holding 3.12M shares signals structured portfolio activity during a period of exceptional price appreciation in an unprofitable business.

10% owner OPKO Health sells 150,000 WGS shares for $4.9M across 3 days; stock up 21.2% in 30 days but company unprofitable with -13.7% revenue decline.

OPKO Health, a 10% shareholder of GeneDx Holdings, executed 3 separate sales totaling 150,000 shares for $4,946,935.00 between July 19–23, 2024, at prices ranging from $32.29 to $33.46 per share. The sales reduced holdings by 4.4% to 3,258,403 shares post-transaction. Notably, this sale occurs against recent bullish price momentum: WGS gained 21.2% over the prior 30 days and 181.6% over 90 days, yet the company reported negative net income of $-20,239,000.00 in the latest quarter and annual revenue declined 13.7% year-over-year. The seller's prior 4 trades at WGS (all June–early July sells) have not yet generated measurable 30- or 90-day outcomes. The disjunction between strong recent stock price appreciation and deteriorating fundamentals (ongoing losses, shrinking revenue) warrants investor attention regarding conviction sustainability at these elevated valuations.

OPKO Health (10% owner) sells 36,118 WGS shares at $28.24; holds 3.43M shares. Stock at 52-week high, -13.7% revenue decline, unprofitable.

OPKO Health sold 36,118 shares of GeneDx on 2024-07-05 at $28.24, representing -1.0% of its pre-transaction holdings of 3.47M shares, leaving a post-transaction position of 3.43M shares. This sale occurred as WGS traded at its 52-week high of $29.81, with the stock up 19.2% over 30 days and 157.9% over 90 days. The company's fundamentals show material deterioration: revenue declined 13.7% year-over-year to $62.4M in the latest quarter, the company reported a net loss of $-20.2M for that period, and full-year net income was negative. Prior sales at WGS on 2024-07-01, 2024-07-02, and 2024-07-03 preceded this transaction, indicating a sequence of dispositions. The sale occurs at elevated valuation relative to fundamental performance, though the insider retains substantial holdings (3.43M shares), suggesting this is not a full exit of the position.

OPKO Health (10% owner) sold 89,082 shares of GeneDx (WGS) over 3 days for $2,457,286.21 at blended avg $27.58

OPKO Health executed 3 separate sales totaling 89,082 shares for $2,457,286.21 between July 1–3, 2024, reducing its stake from 3,558,603 to 3,469,521 shares. The blended average sale price of $27.58 sits near the current price of $28.00 and within proximity to the 52-week high of $28.78. The broader context shows WGS is unprofitable (full-year net income was negative), experiencing annual revenue decline of -13.7%, and trading at a market cap of $731,967,628. This moderately-sized reduction by a major shareholder occurs against a backdrop of deteriorating fundamentals and follows a steep 90-day rally of +209.4%.